Breslin helps innovation-led businesses turn scientific or technical strength into commercial traction. We advise on strategic partnering, licensing and spin-off formation — three closely related routes that share one principle: value is created by finding the right counterparty, not just the right capital.
For early-stage spin-offs, growth-stage biotechs and corporate venture units, the most important decision is rarely how much money to raise. It is which partner, licensee, distributor or strategic ally can validate the technology, expand reach, share development cost or open a clean path to scale. Breslin sits with founders, scientific institutions, boards and corporate sponsors at exactly that decision point.
The right partner is not always the most visible one. Breslin selects counterparties whose capabilities, geography, incentive structure and timing genuinely fit the asset — drawing on a network built over thirty years across pharma, biotech, medtech, agro-industrial and technology counterparties.
In technically complex sectors, partnering decisions are often blocked by translation gaps between science, strategy and commercial fit. Breslin frames the asset, platform or company so that decision-makers on the other side of the table understand the rationale, the data, and the value inflection points without needing to be specialists themselves.
Spin-offs rarely fail on the science. They fail on company structure, ownership logic, milestone framing and investor readiness. Breslin works with founding teams, technology transfer offices and early backers to build a credible commercial vehicle from day one.
Partnering, licensing and spin-off processes are confidence-sensitive. We run targeted, discreet outreach with a clear narrative, structured diligence flow and disciplined follow-up — protecting the asset’s optionality through every conversation.
Life sciences, biotech, pharma, diagnostics, medtech, e-health, industrial biotech, agro/food, energy transition, and selected applied technology.
Breslin combines hands-on transaction experience with deep sector fluency. Partnering and licensing in life sciences and technical industries cannot be run as a generic intermediary process — counterparties expect substance from the first meeting. Spin-offs cannot be run as a financing exercise alone — they need a commercial path. Our team has operated at board level inside biotech and industrial companies, sourced and negotiated partnering deals across Europe and the US and stood up academic spin-offs from leading research institutions including ETH Zurich.
We define the commercial objective, the partnering perimeter and the credible value story. For spin-offs, this stage also covers founding agreement, IP ownership, governance and the early shareholder structure.
We map the relevant universe of partners, licensees, distributors or strategic acquirers — segmented by capability, geography, mandate fit and likely timing. The list is selective, not exhaustive.
We approach counterparties under controlled disclosure, support meeting preparation, manage information flow and coordinate diligence exchange.
We help shape commercial terms, deal structure, milestone economics and governance — through to signing of partnering, licensing or shareholder agreements. For spin-offs we coordinate with corporate finance and legal advisors through the first financing round.
Market mapping, target screening and outreach for cooperation opportunities in functional medical-device materials and anti-infective applications.
Co-founded and supported financing preparation for a protein-misfolding-disorders venture spin out.
Supported founding and initial funding of an ETH Zurich spin-off in partnership with Redalpine.
Whenever the constraint on growth is access — to a market, a development capability, a regulatory pathway or a customer channel — rather than capital. Partnering and licensing can validate the asset, generate revenue and preserve ownership without the dilution of a financing round or the finality of a sale.
Yes. We support university and research-institute spin-offs as well as corporate venture and innovation-unit externalisations. The two have different governance and IP starting points but the commercial path is broadly similar.
Yes. We run cross-border processes routinely across Europe, the UK and the US, and selectively in Asia where the right counterparty sits there.
Before the first financing round, while company structure, IP allocation, ownership and the financing narrative are still being shaped. Early-stage decisions compound — fixing them later is expensive.
Partnering, licensing and spin-off mandates often run alongside a financing process. Where capital raising is the primary need, see our Corporate Finance & Fundraising page; where the priority is finding the right strategic counterparty, this is the right starting point. Many Breslin engagements run both in parallel.
Partner with us
Explore partnering, licensing and spin-off opportunities with Breslin.
